Market Overview

bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors

Share:

bluebird bio, Inc. (Nasdaq:
BLUE
), a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic diseases and T
cell-based immunotherapies for cancer, today announced that it has
appointed Mary Lynne Hedley, Ph.D. to its Board of Directors.

"I'm thrilled to welcome Mary Lynne to the Board," said Nick Leschly,
chief bluebird. "Since founding TESARO in 2010, she has shepherded that
company from a clinical stage to a commercial stage, and has experience
in bringing novel therapies to patients in need. As we continue to
progress our four clinical programs, her broad executive experience,
from clinical research through operations and commercialization, will be
an invaluable resource for the growing bluebird team."

"bluebird bio is a clear leader in the development of gene therapies for
patients with severe genetic diseases, and has shown tremendous promise
with its BCMA program in immuno-oncology," said Dr. Hedley. "I'm excited
to have the opportunity to work closely with the bluebird management
team to help bring the promise of their transformative therapies to
patients in need across multiple products and markets."

Mary Lynne Hedley, Ph.D., co-founded TESARO, Inc., in 2010 and since
that time, has served as the company's President and as a member of its
board of directors. Prior to founding TESARO, Dr. Hedley served as
Executive Vice President of Operations and Chief Scientific Officer of
Abraxis BioScience. She served as Executive Vice President of Eisai
Corporation of North America from January 2008 until July 2009,
following the company's acquisition of MGI PHARMA in January 2008. Dr.
Hedley served in various positions at MGI PHARMA from 2004 through its
acquisition in January 2008, most recently as Executive Vice President
and Chief Scientific Officer. Prior to that, Dr. Hedley co-founded and
served as the President and Chief Executive Officer of ZYCOS, which was
acquired by MGI PHARMA in 2004.

Dr. Hedley completed two consecutive postdoctoral fellowships at Harvard
University and earned her doctoral degree in immunology from the
University of Texas, Southwestern Medical Center and her Bachelor of
Science degree in microbiology from Purdue University. She serves on the
Board of Directors of Millendo Therapeutics Inc. and Youville Place, an
assisted living facility. She served on the Board of Directors of
Receptos, Inc. (NASDAQ:RCPT) from April 2014 until August 2015, when
Receptos, Inc. was acquired by Celgene Corporation.

bluebird bio also announced that with Dr. Hedley's appointment, John
Maraganore, Ph.D. will transition off the Board of Directors. Dr.
Maraganore has been on bluebird bio's Board since 2012.

Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company's
product candidates and research programs. Any
forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk of
cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, risks that the
current or planned clinical trials of the LentiGlobin drug product will
be insufficient to support regulatory submissions or marketing approval
in the United States and European Union, the risk that our
collaborations, including the collaboration with Celgene, will not
continue or will not be successful, and the risk that any one or more of
our product candidates will not be successfully developed, approved or
commercialized.
For a discussion of other risks and
uncertainties, and other important factors, any of which could cause our
actual results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in our annual report
on Form 10-K and our most recent quarterly report on Form 10-Q, as well
as discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of
the release, and bluebird bio undertakes no duty to update this
information unless required by law.

View Comments and Join the Discussion!